Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 4/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30678529 | 1.00 | NOX1 (0.46) | NOX1MEN1KMT2AL3MBTL1ADRA2A | |
| SCHEMBL1418367 | 0.92 | MAOA (0.61) | NOX1MEN1KMT2AL3MBTL1ADRA2A | |
| SCHEMBL29151192 | 0.85 | SNCA (0.64) | L3MBTL1ALDH1A1MAPTSNCAALDH1A3 | |
| SCHEMBL27924965 | 0.81 | ALDH1A1 (0.57) | NOX1MEN1KMT2AL3MBTL1ADRA2A | |
| SCHEMBL8185277 | 0.80 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL29773802 | 0.80 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL30932461 | 0.78 | TRIM24 (0.39) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL29229302 | 0.78 | TRIM24 (0.39) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL8185276 | 0.76 | CYP2A6 (0.46) | MEN1KMT2AMAOAALDH1A1MAPT | |
| SCHEMBL31174406 | 0.76 | PDF (0.43) | ADRA2AADRA2BADRA2CCHRM3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112646131-B | Organic porous polymer and preparation method and application thereof | 华南理工大学 | 2021-11-19 | — | — | CN | claimed |
| CN-112646131-A | Organic porous polymer and preparation method and application thereof | 华南理工大学 | 2021-04-13 | — | — | CN | claimed |
| CN-111225918-B | Toll-like receptor 7 (TLR 7) agonists with tricyclic moieties, conjugates thereof, methods and uses thereof | 百时美施贵宝公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112646131-B | Organic porous polymer and preparation method and application thereof | 华南理工大学 | 2021-11-19 | — | — | CN | disclosed |
| CN-112646131-B | Organic porous polymer and preparation method and application thereof | 华南理工大学 | 2021-11-19 | — | — | CN | disclosed |
| EP-3668868-B1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A TRICYCLIC MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL MYERS SQUIBB CO (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3668868-B1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A TRICYCLIC MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL MYERS SQUIBB CO (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10981914-B2 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Companay (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981914-B2 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Companay (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112646131-A | Organic porous polymer and preparation method and application thereof | 华南理工大学 | 2021-04-13 | — | — | CN | disclosed |
| CN-112646131-A | Organic porous polymer and preparation method and application thereof | 华南理工大学 | 2021-04-13 | — | — | CN | disclosed |
| WO-2019035969-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A TRICYCLIC MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055244-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A TRICYCLIC MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2019-02-21 | — | — | US | disclosed |
| WO-2015161989-A1 | HOLE-TRANSPORT MATERIALS FOR ORGANIC SOLAR CELLS OR ORGANIC OPTICAL SENSORS | BASF SE (DE) | 2015-10-29 | — | — | WO | disclosed |
| EP-2937399-A1 | Hole-transport materials for organic solar cells or organic optical sensors | BASF SE (DE) | 2015-10-28 | — | — | EP | disclosed |
| EP-1817806-B1 | PHENOTHAZINES-S-OXIDES AND S,S-DIOXIDES AS hole and excitonblockers for OLEDs | BASF SE (DE) | 2014-07-30 | — | — | EP | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-1817806-A1 | PHENOTHAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056465-A1 | PHENOTHIAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981914-B2 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR4 | NOX1 1039/4885MEN1 3957/4885KMT2A 3038/4885 |
| US-20190055244-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A TRICYCLIC MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR4 | NOX1 1124/4885MEN1 4024/4885KMT2A 3108/4885 |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | PPOX, SMOX, SORD | NOX1 458/4885MEN1 4804/4885KMT2A 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.